Prelude Therapeutics Inc(PRLD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Prelude Therapeutics Inc (PRLD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRLD at 21.5/100 on a 32-signal composite quality model, placing it at rank #2,765 of 2,962 stocks — the bottom half of the AI-ranked universe. PRLD scores in the top quartile across institutional flow (94.0). Areas of concern include revenue scale (3.7) and profitability (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Prelude Therapeutics Inc reports quarterly revenue of $5.7M, net income of $-13.9M, free cash flow of $-15.6M. Top institutional holders of PRLD by reported 13-F value include ORBIMED ADVISORS, BAKER BROS. ADVISORS, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. PRLD trades on the Nasdaq exchange and files with the SEC under CIK 1678660. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prelude Therapeutics Inc directly from SEC EDGAR.